Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.

Molecular cancer research : MCR - 1 Mar 2015

Li Zhen, Sun Yin, Chen Xufeng, Squires Jill, Nowroozizadeh Behdokht, Liang Chaozhao, Huang Jiaoti

Abstract excerpt

UNLABELLED: Prostatic small cell neuroendocrine carcinoma (SCNC) is a rare but aggressive form of prostate cancer that is negative for androgen receptor (AR) and not responsive to hormonal therapy. The molecular etiology of this prostate cancer variant is not well understood; however, mutation of the p53 (TP53) tumor suppressor in prostate neuroendocrine cells inactivates the IL8-CXCR2-p53 pathway that normally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A
Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Small Cell

Share to F-Box Proteins

Share to F-Box-WD Repeat-Containing Protein 7

Share to MicroRNAs

Share to Prostatic Neoplasms

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 25512615
DOI: 10.1158/1541-7786.MCR-14-0277-T
PMCID: PMC4369163

Genes

AURKA
CXCR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.PMID 25512615Read ↗

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.Semantic proximity Read ↗

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.Semantic proximity Read ↗

The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.Semantic proximity Read ↗

Nuclear iASPP may facilitate prostate cancer progression.Semantic proximity Read ↗

TP53 loss‐of‐function causes vulnerability to autophagy inhibition in aggressive prostate cancerSemantic proximity Read ↗

Tumor suppressor gene p53 mutations in human prostate cancer.Semantic proximity Read ↗

TP53 Inhibited AR Signaling Promote Enzalutamide Resistance in LNCaP cellSemantic proximity Read ↗

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3Semantic proximity Read ↗

Alterations of p53 are common in early stage prostate cancer.Semantic proximity Read ↗

Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer CellsSemantic proximity Read ↗

Nicotine Promotes WRL68 Cells Proliferation Due to the Mutant p53 Gain-of-Function by Activating CDK6-p53-RS-PIN1-STAT1 Signaling Pathway.Semantic proximity Read ↗

Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.